Research progress on adaptability of patients with chemotherapy-induced peripheral neuropathy

ZHOU Xiao; DING Caiyan; LIU Hui; ZHENG Suhua; SUN Zhiqin

doi:10.7619/jcmp.20214940

Journal of Clinical Medicine in Practice > 2022 > 26(8): 137-142. > DOI: 10.7619/jcmp.20214940

ZHOU Xiao, DING Caiyan, LIU Hui, ZHENG Suhua, SUN Zhiqin. Research progress on adaptability of patients with chemotherapy-induced peripheral neuropathy[J]. Journal of Clinical Medicine in Practice, 2022, 26(8): 137-142. DOI: 10.7619/jcmp.20214940

Citation:

PDF (934 KB)

Research progress on adaptability of patients with chemotherapy-induced peripheral neuropathy

1.
Changzhou Clinical Medical College Affiliated to Nanjing Medical University, Changzhou, Jiangsu, 213000
2.
Nursing Teaching and Research Department, Changzhou Second People's Hospital Affiliated to Nanjing Medical University, Changzhou, Jiangsu, 213000
3.
College of Nursing of Bengbu Medical College, Bengbu, Anhui, 233000
4.
Department of Oncology, Changzhou Second People's Hospital Affiliated to Nanjing Medical University, Changzhou, Jiangsu, 213000

More Information

Received Date: December 14, 2021
Available Online: April 27, 2022
Published Date: April 27, 2022

Graphical Abstract

Abstract

Abstract

Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect of chemotherapy, and is one of the symptoms that cannot be effectively resolved, which seriously affects the physical and mental health and adaptation level of patients. This paper reviewed the overview of adaptation, assessment tools and CIPN scale of adaptation, influencing factors and intervention measures of adaptation in patients with chemotherapy-induced peripheral neurotoxicity. The factors influencing the adaptation level of patients with chemotherapy-induced peripheral neurotoxicity are complex, the intervention methods need to be further explored and improved, and the intervention effects need to be further verified, which can provide reference for further clinical application and in-depth research in the future.
- chemotherapy-Induced peripheral neuropathy,
- chemotherapy side effects,
- adaptation,
- influencing factors

FullText(HTML)

References (52)

References

[1]	LOPRINZI C L, LACCHETTI C, BLEEKER J, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update[J]. J Clin Oncol, 2020, 38(28): 3325-3348. doi: 10.1200/JCO.20.01399
[2]	TIMMINS H C, MIZRAHI D, LI T, et al. Metabolic and lifestyle risk factors for chemotherapy-induced peripheral neuropathy in taxane and platinum-treated patients: a systematic review[J]. J Cancer Surviv, 2021.
[3]	SELVY M, PEREIRA B, KERCKHOVE N, et al. Long-term prevalence of sensory chemotherapy-induced peripheral neuropathy for 5 years after adjuvant FOLFOX chemotherapy to treat colorectal cancer: amulticenter cross-sectional study[J]. J Clin Med, 2020, 9(8): 2400. doi: 10.3390/jcm9082400
[4]	BONHOF C S, VAN DE POLL-FRANSE L V, VISSERS P A J, et al. Anxiety and depression mediate the association between chemotherapy-induced peripheral neuropathy and fatigue: results from the population-based PROFILES registry[J]. Psycho-oncology, 2019, 28(9): 1926-1933. doi: 10.1002/pon.5176
[5]	BULLS H W, HOOGLAND A I, SMALL B J, et al. Lagged relationships among chemotherapy-induced peripheral neuropathy, sleep quality, and physical activity during and after chemotherapy[J]. Ann Behav Med, 2021, 55(9): 844-852. doi: 10.1093/abm/kaaa101
[6]	TROMPETTER H R, BONHOF C S, VANDE POLL-FRANSE L V, et al. Exploring the relationship among dispositional optimism, health-related quality of life, and CIPN severity among colorectal cancer patients with chronic peripheral neuropathy[J]. Support Care Cancer, 2022, 30(1): 95-104. doi: 10.1007/s00520-021-06352-0
[7]	ROY C. Extending the Roy adaptation model to meet changing global needs[J]. Nurs Sci Q, 2011, 24(4): 345-351. doi: 10.1177/0894318411419210
[8]	姚静静, 陈如男, 刘砚燕, 等. 癌症患者心理社会适应水平及其影响因素[J]. 解放军护理杂志, 2013, 30(7): 7-11, 16. https://www.cnki.com.cn/Article/CJFDTOTAL-JFHL201307004.htm
[9]	DE RIDDER D, GEENEN R, KUIJER R, et al. Psychological adjustment to chronic disease[J]. Lancet, 2008, 372(9634): 246-255. doi: 10.1016/S0140-6736(08)61078-8
[10]	DEROGATIS L R. The psychosocial adjustment to illness scale (PAIS)[J]. J Psychosom Res, 1986, 30(1): 77-91. doi: 10.1016/0022-3999(86)90069-3
[11]	姚静静. 癌症患者适应水平的横断面调查及其预测因素分析[D]. 上海: 第二军医大学, 2013.
[12]	TANAY M A, ARMES J. Lived experiences and support needs of women who developed chemotherapy-induced peripheral neuropathy following treatment for breast and ovarian cancer[J]. Eur J Cancer Care (Engl), 2019, 28(3): e13011.
[13]	CHAN C W, CHENG H L, AU S K, et al. Living with chemotherapy-induced peripheral neuropathy: Uncovering the symptom experience and self-management of neuropathic symptoms among cancer survivors[J]. Eur J Oncol Nurs, 2018, 36: 135-141. doi: 10.1016/j.ejon.2018.09.003
[14]	ZHI W I, BASER R E, KWON A, et al. Characterization of chemotherapy-induced peripheral neuropathy using patient-reported outcomes and quantitative sensory testing[J]. Breast Cancer Res Treat, 2021, 186(3): 761-768. doi: 10.1007/s10549-020-06079-2
[15]	TAN A C, MCCRARY J M, PARK S B, et al. Chemotherapy-induced peripheral neuropathy-patient-reported outcomes compared with NCI-CTCAE grade[J]. Support Care Cancer, 2019, 27(12): 4771-4777. doi: 10.1007/s00520-019-04781-6
[16]	CAVALETTI G, FRIGENI B, LANZANI F, et al. Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools[J]. Eur J Cancer, 2010, 46(3): 479-494. doi: 10.1016/j.ejca.2009.12.008
[17]	CORNBLATH D R, CHAUDHRY V, CARTER K, et al. Total neuropathy score: validation and reliability study[J]. Neurology, 1999, 53(8): 1660-1664. doi: 10.1212/WNL.53.8.1660
[18]	CALHOUN E A, WELSHMAN E E, CHANG C H, et al. Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy[J]. Int J Gynecol Cancer, 2003, 13(6): 741-748.
[19]	POSTMA T J, AARONSON N K, HEIMANS J J, et al. The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20[J]. Eur J Cancer, 2005, 41(8): 1135-1139. doi: 10.1016/j.ejca.2005.02.012
[20]	MONFORT S M, PAN X L, PATRICK R, et al. Gait, balance, and patient-reported outcomes during taxane-based chemotherapy in early-stage breast cancer patients[J]. Breast Cancer Res Treat, 2017, 164(1): 69-77. doi: 10.1007/s10549-017-4230-8
[21]	WONG M L, COOPER B A, PAUL S M, et al. Age-related differences in patient-reported and objective measures of chemotherapy-induced peripheral neuropathy among cancer survivors[J]. Support Care Cancer, 2019, 27(10): 3905-3912. doi: 10.1007/s00520-019-04695-3
[22]	DROTT J, STARKHAMMAR H, KJELLGREN K, et al. Neurotoxic side effects early in the oxaliplatin treatment period in patients with colorectal cancer[J]. Oncol Nurs Forum, 2018, 45(6): 690-697.
[23]	GROVER S, HILL-KAYSER C E, VACHANI C, et al. Patient reported late effects of gynecological cancer treatment[J]. Gynecol Oncol, 2012, 124(3): 399-403. doi: 10.1016/j.ygyno.2011.11.034
[24]	HUNG H W, LIU C Y, CHEN H F, et al. Impact of chemotherapy-induced peripheral neuropathy on quality of life in patients with advanced lung cancer receiving platinum-based chemotherapy[J]. Int J Environ Res Public Health, 2021, 18(11): 5677. doi: 10.3390/ijerph18115677
[25]	LU L C, TSAY S L, CHANG S Y, et al. Daily activity, mood, and quality of life in colorectal cancer patients with chemotherapy-induced peripheral neuropathy: a mediation effect analysis[J]. Cancer Med, 2019, 8(3): 963-971. doi: 10.1002/cam4.1976
[26]	SIMON N B, DANSO M A, ALBERICO T A, et al. The prevalence and pattern of chemotherapy-induced peripheral neuropathy among women with breast cancer receiving care in a large community oncology practice[J]. Qual Life Res, 2017, 26(10): 2763-2772. doi: 10.1007/s11136-017-1635-0
[27]	TRENDOWSKI M R, LUSK C M, RUTERBUSCH J J, et al. Chemotherapy-induced peripheral neuropathy in African American cancer survivors: risk factors and quality of life outcomes[J]. Cancer Med, 2021, 10(22): 8151-8161. doi: 10.1002/cam4.4328
[28]	ZHONG J, GUO Z H, FAN L P, et al. ABCB1 polymorphism predicts the toxicity and clinical outcome of lung cancer patients with taxane-based chemotherapy[J]. Thorac Cancer, 2019, 10(11): 2088-2095. doi: 10.1111/1759-7714.13184
[29]	MCNEISH B L, RICHARDSON J K, BELL S G, et al. Chemotherapy-induced peripheral neuropathy increases nontraumatic fracture risk in breast cancer survivors[J]. JBMR Plus, 2021, 5(8): e10519.
[30]	BONHOF C S, TROMPETTER H R, VREUGDENHIL G, et al. Painful and non-painful chemotherapy-induced peripheral neuropathy and quality of life in colorectal cancer survivors: results from the population-based PROFILES registry[J]. Support Care Cancer, 2020, 28(12): 5933-5941. doi: 10.1007/s00520-020-05438-5
[31]	BATTAGLINI E, GOLDSTEIN D, GRIMISON P, et al. Chemotherapy-induced peripheral neurotoxicity in cancer survivors: predictors of long-term patient outcomes[J]. J Natl ComprCancNetw, 2021, 19(7): 821-828.
[32]	COX-MARTIN E, TRAHAN L H, COX M G, et al. Disease burden and pain in obese cancer patients with chemotherapy-induced peripheral neuropathy[J]. Support Care Cancer, 2017, 25(6): 1873-1879. doi: 10.1007/s00520-017-3571-5
[33]	GOMEZ D, JIMENEZ-FONSECA P, FERNÁNDEZ A M, et al. Impact of obesity on quality of life, psychological distress, and coping on patients with colon cancer[J]. Oncologist, 2021, 26(5): e874-e882. doi: 10.1002/onco.13687
[34]	KANZAWA-LEE G A, LARSON J L, RESNICOW K, et al. Exercise effects on chemotherapy-induced peripheral neuropathy: acomprehensive integrative review[J]. Cancer Nurs, 2020, 43(3): E172-E185. doi: 10.1097/NCC.0000000000000801
[35]	WILCOXON A, KOBERK M, VIELE C, et al. Association between physical activity levels and chemotherapy-induced peripheral neuropathy severity in cancer survivors[J]. Oncol Nurs Forum, 2020, 47(6): 703-719. doi: 10.1188/20.ONF.703-719
[36]	GREENLEE H, HERSHMAN D L, SHI Z X, et al. BMI, lifestyle factors and taxane-induced neuropathy in breast cancer patients: the pathways study[J]. J Natl Cancer Inst, 2016, 109(2): djw206.
[37]	KLECKNER I R, JUSKO T A, CULAKOVA E, et al. Longitudinal study of inflammatory, behavioral, clinical, and psychosocial risk factors for chemotherapy-induced peripheral neuropathy[J]. Breast Cancer Res Treat, 2021, 189(2): 521-532. doi: 10.1007/s10549-021-06304-6
[38]	RO S M, WOO I S. Long-term efficacy and safety of duloxetine in the management of painful chemotherapy induced peripheral neuropathy[J]. J Clin Oncol, 2017, 35(31_suppl): 236. doi: 10.1200/JCO.2017.35.31_suppl.236
[39]	MIASKOWSKI C, PAUL S M, MASTICK J, et al. Associations between perceived stress and chemotherapy-induced peripheral neuropathy and otoxicity in adult cancer survivors[J]. J Pain Symptom Manage, 2018, 56(1): 88-97. doi: 10.1016/j.jpainsymman.2018.02.021
[40]	POULIN P A, ROMANOW H C, RAHBARI N, et al. The relationship between mindfulness, pain intensity, pain catastrophizing, depression, and quality of life among cancer survivors living with chronic neuropathic pain[J]. SupportCare Cancer, 2016, 24(10): 4167-4175.
[41]	LEE K M, JUNG D, HWANG H, et al. Pre-treatment anxiety is associated with persistent chemotherapy-induced peripheral neuropathy in women treated with neoadjuvant chemotherapy for breast cancer[J]. J Psychosom Res, 2018, 108: 14-19. doi: 10.1016/j.jpsychores.2018.02.012
[42]	KOLB N A, SMITH A G, SINGLETON J R, et al. Chemotherapy-related neuropathic symptom management: a randomized trial of an automated symptom-monitoring system paired with nurse practitioner follow-up[J]. Support Care Cancer, 2018, 26(5): 1607-1615. doi: 10.1007/s00520-017-3970-7
[43]	KNOERL R, WELLER E, HALPENNY B, et al. Exploring the efficacy of an electronic symptom assessment and self-care intervention to preserve physical function in individuals receiving neurotoxic chemotherapy[J]. BMC Cancer, 2018, 18(1): 1203. doi: 10.1186/s12885-018-5093-z
[44]	DROTT J, STARKHAMMAR H, KJELLGREN K, et al. The trajectory of neurotoxic side effects' impact on daily life: a qualitative study[J]. Support Care Cancer, 2016, 24(8): 3455-3461. doi: 10.1007/s00520-016-3179-1
[45]	李玉梅, 黄瑛, 张燕, 等. 肺癌患者对化疗致周围神经炎症状心理体验的质性研究[J]. 上海护理, 2018, 18(5): 36-39. doi: 10.3969/j.issn.1009-8399.2018.05.009
[46]	SALGADO T M, QUINN C S, KRUMBACH E K, et al. Reporting of paclitaxel-induced peripheral neuropathy symptoms to clinicians among women with breast cancer: a qualitative study[J]. Support Care Cancer, 2020, 28(9): 4163-4172. doi: 10.1007/s00520-019-05254-6
[47]	GALANTINO M L, TIGER R, BROOKS J, et al. Impact of somatic Yoga and meditation on fall risk, function, and quality of life for chemotherapy-induced peripheral neuropathy syndrome in cancer survivors[J]. Integr Cancer Ther, 2019, 18: 1534735419850627.
[48]	KNOERL R, SMITH E M L, BARTON D L, et al. Self-guided online cognitive behavioral strategies for chemotherapy-induced peripheral neuropathy: amulticenter, pilot, randomized, wait-list controlled trial[J]. J Pain, 2018, 19(4): 382-394. doi: 10.1016/j.jpain.2017.11.009
[49]	DHAWAN S, ANDREWS R, KUMAR L, et al. A randomized controlled trial to assess the effectiveness of muscle strengthening and balancing exercises on chemotherapy-induced peripheral neuropathic pain and quality of life among cancer patients[J]. Cancer Nurs, 2020, 43(4): 269-280. doi: 10.1097/NCC.0000000000000693
[50]	BLAND K A, KIRKHAM A A, BOVARD J, et al. Effect of exercise on taxanechemotherapy-induced peripheral neuropathy in women with breast cancer: arandomized controlled trial[J]. Clin Breast Cancer, 2019, 19(6): 411-422. doi: 10.1016/j.clbc.2019.05.013
[51]	HAN X Y, WANG L J, SHI H F, et al. Acupuncture combined with methylcobalamin for the treatment of chemotherapy-induced peripheral neuropathy in patients with multiple myeloma[J]. BMC Cancer, 2017, 17(1): 40. doi: 10.1186/s12885-016-3037-z
[52]	IRAVANI S, KAZEMI MOTLAGH A H, EMAMI RAZAVI S Z, et al. Effectiveness of acupuncture treatment on chemotherapy-induced peripheral neuropathy: apilot, randomized, Assessor-blinded, controlled trial[J]. Pain Res Manag, 2020, 2020: 2504674.

Cited By

Get Citation

PDF

XML

Article views (254) PDF downloads (22)

Turn off MathJax

Article Contents

Abstract

References

Research progress on adaptability of patients with chemotherapy-induced peripheral neuropathy

Abstract

References

Catalog

Export File

Citation

Format

Content